Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.68 |
| ▸ | CA1 | P00915 | 4/20 | 0.68 |
| ▸ | GRN | P28799 | 1/20 | 0.67 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.49 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4753159 | 1.00 | CA2 (0.68) | CA2CA1GRNSORT1MEN1 | |
| SCHEMBL8185308 | 1.00 | CA2 (0.68) | CA2CA1GRNSORT1MEN1 | |
| SCHEMBL4419910 | 0.84 | GRN (0.63) | GRNSORT1MEN1KMT2ACYP1A2 | |
| SCHEMBL15787063 | 0.84 | CA2 (0.69) | CA2CA1GRNSORT1MEN1 | |
| SCHEMBL11103451 | 0.82 | CA2 (0.71) | CA2CA1MEN1KMT2ANPC1 | |
| SCHEMBL11103438 | 0.82 | CA2 (0.71) | CA2CA1MEN1KMT2ANPC1 | |
| SCHEMBL13754407 | 0.81 | GRN (0.60) | CA2CA1GRNSORT1MEN1 | |
| SCHEMBL8338918 | 0.81 | CA2 (0.61) | CA2CA1MEN1KMT2AGPR139 | |
| SCHEMBL2172294 | 0.81 | CA2 (0.61) | CA2CA1MEN1KMT2AGPR139 | |
| SCHEMBL24283484 | 0.80 | GRN (1.00) | CA2CA1GRNSORT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008149103-A1 | METHODS OF ASSESSING AND TREATING MULTIPLE-ORGAN FAILURE | UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2008-12-11 | — | — | WO | claimed |
| US-20200345745-A1 | KYNURENINE 3-MONOOXYGENASE (KMO) INHIBITORS, AND USES AND COMPOSITIONS THEREOF | UNIVERSITY OF LEICESTER (GB) | 2020-11-05 | — | — | US | disclosed |
| EP-3713935-A1 | KYNURENINE 3-MONOOXYGENASE (KMO) INHIBITORS, AND USES AND COMPOSITIONS THEREOF | University of Leicester (GB) | 2020-09-30 | — | — | EP | disclosed |
| WO-2019102186-A1 | KYNURENINE 3-MONOOXYGENASE (KMO) INHIBITORS, AND USES AND COMPOSITIONS THEREOF | UNIVERSITY OF LEICESTER (GB) | 2019-05-31 | — | — | WO | disclosed |
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| WO-2008149103-A1 | METHODS OF ASSESSING AND TREATING MULTIPLE-ORGAN FAILURE | UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2008-12-11 | — | — | WO | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
| US-6107069-A | NUCLEOTIDE AND AMINO ACID SEQUENCES; FOR CLONING; FOR HYBRIDIZATION PROBES TO SCREEN LIBRARIES | PHARMACIA & UPJOHN S.P.A. (IT) | 2000-08-22 | — | — | US | disclosed |
| US-5958910-A | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5877193-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0819681-A2 | N-(4-Aryl-thiazol-2-yl)-sulfonamides and their use | F. HOFFMANN-LA ROCHE AG (CH) | 1998-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345745-A1 | KYNURENINE 3-MONOOXYGENASE (KMO) INHIBITORS, AND USES AND COMPOSITIONS THEREOF | KMO, KYNU, DAO | CA2 2854/4885CA1 1677/4885GRN 924/4885 |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | CA2 4436/4885CA1 4706/4885GRN 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.